Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1999-10-29
2003-09-02
Travers, Russell (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S008100
Reexamination Certificate
active
06613741
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates generally to the iron binding protein lactoferrin. In particular, it relates to the use of lactoferrin to treat or prevent insult-induced metabolic imbalance in humans and animals, and its use for the manufacture of a medicament for the treatment or prevention of insult-induced metabolic imbalance in humans and animals.
BACKGROUND OF THE INVENTION
Homeostasis is a state of equilibrium in the internal environment. The integrity of such system is continuously disturbed by stimuli that tend to create an internal imbalance. In response to prolonged stimuli, the compensatory mechanisms often do not restore the balance. This may, consequently lead to the activation of self-perpetuating, autodestructive mechanisms including death. The central pathway involved in the insult-induced metabolic imbalance may depend in part on the nature of the stimuli, but the hypo- or hyper-thermia appears to be common for many forms of insult. The energy balance of the internal environment is controlled by the central nervous system (CNS) and regulated by the decrease (chills) or increase (fever) of our body temperature. Whether the insult is microbial infection, inflammation or trauma the internal environment responds to those insults by activating thermoregulatory mechanisms that coincide with the production and release of many immunomodulatory substances. Cytokines, prostaglandins, and different growth factors and hormones are released from specific cells to restore the internal metabolic balance, which largely depends on the energy equilibrium.
The significance of lactoferrin in health and disease has been the subject of several reviews. A most recent publication entitled “
Lactoferrin: Molecular Structure and Biological Function
” has been published in 1995 by B. Lonnerdal and S. Iyer in Ann. Rev. Nutr., 15:93-110.
Lactoferrin is a multifunctional protein expressed in a variety of cell types under different mechanisms of control. The primary function of lactoferrin seems to be a protection against pathogenic bacteria. By virtue of sequestering iron, lactoferrin may control development of potential infections. In addition, it can kill a wide variety of Gram-negative and Gram-positive bacteria by direct interaction with the cell surface, a mode of action that is not dependent on iron. Lactoferrin is thought to be an important component of the defense system, active at mucosal surfaces, including the gastrointestinal tract. Various immunoregulatory and anti-infective roles for lactoferrin have been reviewed by J. Brock in an article entitled “
Lactoferrin: a multifunctional immunoregulatory protein?”
and published in Immunology Today (1995), 16:417-419.
Although, considerable data from in vitro experiments indicate several physiological roles for lactoferrin, there is no firm evidence concerning its actual physiological function from in vivo studies. For example, in a review by Roy D. Byens and Werner R. Bezwoda entitled “Lactoferrin and the inflammatory response” and published in the book:
Lactoferrin: Structure and Function,
pp 133-141, (1994), a relationship between plasma lactoferrin and granulocyte activity in sepsis is mentioned. However, the biological function of the significant amounts of lactoferrin in plasma of septic patients is as yet incompletely understood.
In another review entitled “
The role of lactoferrin as an anti
-
inflammatory molecule
” by Bradley E. Britigan, Jonathan S. Serody, and Myron S. Cohen and published in the book:
Lactoferrin: Structure and Function,
pp 143-156, (1994), the role of lactoferrin in inflammation is suggested to be played at two different levels: (i) as an antioxidant, capable of binding free iron, and (ii) as an endotoxin scavenger, capable of reducing lipopolysaccharide (LPS)-induced toxicity. Furthermore, the ability of lactoferrin to bind LPS in vitro has been confirmed by E. Elass-Rochard, A. Roseanu, D. Legrand, M. Trif, V. Salmon, C. Motas, J. Montreuil and G. Spik in an article entitled “
Lactoferrin
-
lipopolysaccharide interaction: involvement of the
28-34
loop region of human lactoferrin in the high
-
affinity binding to
Escheria coli
055
B
5
lipopolysaccharide”
, published in Biochem. J. (1995) 312:839-845. However, in vivo studies have to confirm lactoferrin's role in those internal metabolic responses during inflammatory processes.
In another article entitled: “Lactoferrin can protect mice against a lethal dose of
Escherichia coli
in experimental infection in vivo” by T. Zagulski, P. Lipinski, A. Zagulska, S. Broniek and Z. Jarzabek, published in 1989 in Br. J. Exp. Path., 79:697-704, the use of lactoferrin is disclosed to increase the survival of mice injected with a lethal dose of bacteria. However there is no disclosure that the intravenously administered lactoferrin has any effect on the gut function and structure to give such protection.
Relevant patents are also silent as to the role of lactoferrin in insult-induced metabolic activity.
U.S. Pat. No. 4,977,137 of Nichols et al. discloses milk lactoferrin as a dietary ingredient which promotes growth of the gastrointestinal tract of human infants and newborn nonhuman animals immediately on birth. Nichols discusses the use of lactoferrin in the management of short gut syndrome, an anatomical dysfunction rather than an insult-induced metabolic imbalance.
U.S. Pat. No. 5,240,909 of Nitsche relates to the use of lactoferrin as an agent for the prophylactic and therapeutic treatment of the toxic effects of endotoxins. Nitche discloses that the lactoferrin used according to his invention has the ability to neutralize endotoxin and must have bound to it either iron or another metal to be effective.
U.S. Pat. No. 5,066,491 of Stott et al. encompasses a method of disease treatment utilizing a therapeutically effective product produced from ordinary milk whey.
SUMMARY OF THE INVENTION
The method of the present invention provides a novel use of the iron binding protein lactoferrin to prevent or treat insult-induced metabolic imbalance in humans and other animals. In one embodiment of the present invention there is provided a method to use lactoferrin to modulate such metabolic imbalance through the gastrointestinal tract. In a further embodiment, the present invention relates to the use of lactoferrin for the manufacture of a medicament for the prevention or treatment of insult-induced metabolic imbalance in humans and animals. In yet a further embodiment, the present invention relates to the use of lactoferrin for the manufacture of a medicament for the modulation of such metabolic imbalance through the gastrointestinal tract.
REFERENCES:
patent: 4977137 (1990-12-01), Nichols et al.
patent: 5240909 (1993-08-01), Nitsche
patent: 5466669 (1995-11-01), Konig et al.
patent: 5531989 (1996-07-01), Paul
patent: 5561109 (1996-10-01), Mita et al.
patent: 5770580 (1998-06-01), Ledley et al.
Britigan et al. “The Role of Lactoferrin as an Anti-inflammatory molecule,” 1994, Advances in Experimental Medicine and Biology, vol. 357, p. 143-156.*
Medline Abstract, AN 87105804, Fritsch et al., 1987.*
“The Natural History of the Systemic Inflammatory Response Syndrome (SIRS)”, M. Sugfrids Raupel-Frauste et al, JAMA, Jan. 11, 1995—vol. 273, No. 2, pp. 117-123.
Castro Gilbert A.
Kruzel Marian L.
Ferro Dynamics Inc.
Myers Kurt J.
Travers Russell
Wang Shengjun
LandOfFree
Method for treating aseptic SIRS in humans and other animals does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating aseptic SIRS in humans and other animals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating aseptic SIRS in humans and other animals will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3084686